Table 1.

Clinicopathological and Molecular Findings of MM Patients Included in the Study

Patient no.	Gender/Age	MC	LDH	β2	Stage*	BG	BS	Cyclin D1 IHC	FISH
1	M/67	Aλ	0	1	IA/N	II	II	–	–
2	M/66	Aκ	0	0	IA/Y	I	II	–	ND
3	M/51	Aκ	0	1	IA/N	I	I	–	–
4	F/66	Gκλ	0	1	IA/Y	I	II	–	+11
5	F/49	Gκ	0	0	IA/Y	I	III	+	t(11;14)
6	F/46	Aλ	0	0	IA/N	II	I	–	–
7	F/56	Gλ	0	1	IA/N	II	II	–	–
8	M/57	Gκ	0	0	IA/Y	I	I	+	ND
9	F/50	Gκ	0	0	IA/Y	II	I	–	–
10	F/66	λ	1	1	IA/N	I	II	–	–
11	M/74	Aλ	0	1	IA/N	I	I	–	+11
12	F/55	Gκ/Aκ	0	1	IA/Y	I	I	–	–
13	F/85	Aλ	0	1	IA/N	I	I	–	–
14	F/53	Gκ	0	0	IA/N	I	I	–	ND
15	F/48	Aλ	0	0	IA/N	I	I	–	ND
16	M/65	Gκ	1	1	IA/N	I	I	–	–
17	M/54	Aκ	0	1	IA/N	II	I	–	+11
18	M/71	Gλ	0	0	IA/N	II	I	–	–
19	M/48	Gκ	0	1	IA/N	I	I	–	–
20	F/78	Gλ	0	1	IA/N	I	I	–	ND
21	F/46	Gλ	0	0	IA/N	I	II	–	–
22	F/72	Gκ	0	1	IA/N	I	II	–	+11
23	F/56	Gκ	0	0	IA/N	I	I	–	–
24	F/70	Gκ	0	1	IIA/Y	I	I	–	–
25	F/74	Aκ	0	1	IIA/Y	I	I	–	–
26	M/36	Dκ	1	1	IIA/Y	I	III	+	t(11;14)
27	M/77	Gκ	0	1	IIA/Y	I	I	–	+11
28	M/44	Gκ	0	0	IIA/Y	I	II	–	+11
29	M/67	Aλ	0	1	IIA/Y	II	III	+	ND
30	M/67	Gκ	0	1	IIIA/Y	III	III	–	+11
31	F/61	Ak	0	1	IIIA/Y	I	III	–	+11
32	F/65	λ	0	0	IIIA/Y	II	I	–	ND
33	F/62	λ	0	1	IIIA/Y	I	I	+	t(11;14)
34	M/53	Aκ	0	1	IIIA/Y	I	III	+	t(11;14)
35	F/71	λ	0	1	IIIA/Y	II	III	–	–
36	M/76	Aλ	0	1	IIIA/Y	I	II	+	+11
37	F/47	Gλ	0	0	IIIA/N	I	II	+	–
38	M/57	Gκ	1	1	IIIB/Y	III	III	–	+11
39	M/78	Gκ	0	1	IIIB/Y	I	III	+	t(11;14)
40	F/75	Gκ	0	1	IIIB/Y	I	II	–	–
41	F/56	Gκ	0	0	R	R	R	+	+11
42	F/68	Gλ	0	0	R	R	R	–	–
43	M/69	Gκ	0	1	R	R	R	–	ND
44	M/50	Aλ	0	0	R	R	R	–	ND
45	F/78	Gκ	0	1	R	R	R	–	+11
46	M/51	Aκ	0	1	R	R	R	–	+11
47	F/68	Gκ	0	1	R	R	R	+	t(11;14)
48	M/72	Aλ	0	1	R	R	R	+	t(11;14)

MC, monoclonal component; BG, Bartl’s histologic grade; BS, Bartl’s histologic stage; LDH, lactic dehyrogenase; ND, not done.

*Absence (N) or presence (Y) of clinical symptoms; R, relapse.

LDH: 0 ≤ 460 U/l; 1 > 460 U/l; β2: 0 ≤ 2.6 mg/ml; 1 > 2.2 mg/ml.